Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ADAG
ADAG logo

ADAG Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Adagene Inc (ADAG) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.360
1 Day change
-0.88%
52 Week Range
4.750
Analysis Updated At
2026/05/28
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

ADAG is not a clear good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The technical setup is constructive, but the absence of recent news, no strong proprietary buy signal, neutral trading activity, and no financial snapshot to confirm current growth quality make this more of a watchlist name than an immediate purchase. If forced to act now, I would not rate it a strong buy.

Technical Analysis

Trend is short-term bullish. MACD histogram is positive and expanding, and the moving averages are aligned bullishly with SMA_5 above SMA_20 above SMA_200, which supports upward momentum. RSI_6 at 67.94 is near overbought but still not extreme, suggesting momentum is positive without a strong reversal signal yet. Price is sitting at 4.00, just below resistance at 4.144 and above pivot support at 3.697, so the stock is in an acceptable trend but not at an especially attractive entry after a recent move. The probabilistic stock trend data also shows modest near-term upside, but not enough to override the lack of stronger conviction signals.

Positive Catalysts

  • ["Guggenheim raised the price target to $10 from $9 and kept a Buy rating.", "Bullish moving average structure indicates favorable trend momentum.", "Positive and expanding MACD histogram supports continued short-term strength.", "Stock trend model suggests a 60% chance of gains over the next day, week, and month."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no fresh event-driven catalyst.", "No AI Stock Picker signal today.", "No SwingMax signal recently.", "Hedge funds are neutral and insiders are neutral, showing no meaningful accumulation signal.", "No recent congress trading data available.", "RSI is near overbought territory, making the current price less ideal for an impatient entry."]

Financial Performance

No usable financial snapshot was provided, so the latest quarter financial performance cannot be assessed. As a result, there is no confirmed recent-quarter growth trend to support a long-term buy decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Wall Street sentiment is mildly positive. Guggenheim increased its price target to $10 from $9 and reaffirmed a Buy rating, which is constructive. However, the broader picture is not strongly convincing because there is no recent cluster of upgrades, no fresh news catalyst, and no notable insider or hedge fund buying trend. Overall, analysts lean bullish, but the conviction level appears moderate rather than high.

Wall Street analysts forecast ADAG stock price to rise
2 Analyst Rating
Wall Street analysts forecast ADAG stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.390
sliders
Low
8
Averages
8.5
High
9
Current: 3.390
sliders
Low
8
Averages
8.5
High
9
Guggenheim
Buy
maintain
$9 -> $10
AI Analysis
2026-04-06
Reason
Guggenheim
Price Target
$9 -> $10
AI Analysis
2026-04-06
maintain
Buy
Reason
Guggenheim raised the firm's price target on Adagene to $10 from $9 and keeps a Buy rating on the shares. The firm is updating its model for FY25 earnings, the ATM offering, and modest adjustments to its assumptions for lead asset muzastotug.
Guggenheim
initiated
$9
2025-11-24
Reason
Guggenheim
Price Target
$9
2025-11-24
initiated
Reason
As previously reported, Guggenheim initiated coverage of Adagene with a Buy rating and $9 price target. The company's lead product candidate muzastotug is currently in Phase 2 for patients with late-line microsatellite stable colorectal cancer without liver metastases, notes the analyst. The company has reported "compelling" Phase 1 data for muzastotug plus pembrolizumab that exceed current standard of care benchmarks in third-line and later CRC, according to the analyst, who calls this "an area of significant unmet need."
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ADAG
Unlock Now

People Also Watch